Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGEN Stock Forecast 2025-2026
$144.75
Current Price
$8.16B
Market Cap
Buy 13
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to RGEN Price Targets
+55.4%
To High Target of $225.00
+31.3%
To Median Target of $190.00
-3.3%
To Low Target of $140.00
RGEN Price Momentum
+10.0%
1 Week Change
+8.5%
1 Month Change
-13.1%
1 Year Change
+0.6%
Year-to-Date Change
-20.7%
From 52W High of $182.52
+40.6%
From 52W Low of $102.97
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Repligen (RGEN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RGEN and similar high-potential opportunities.
Latest RGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, RGEN has a bullish consensus with a median price target of $190.00 (ranging from $140.00 to $225.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $144.75, the median forecast implies a 31.3% upside. This outlook is supported by 13 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 55.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGEN Analyst Ratings
13
Buy
6
Hold
0
Sell
RGEN Price Target Range
Low
$140.00
Average
$190.00
High
$225.00
Current: $144.75
Latest RGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Canaccord Genuity | Hold | Maintains | $0.00 | |
| Apr 16, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $150.00 |
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | In-Line | Initiates | $155.00 |
| Feb 21, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $170.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| Feb 21, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $205.00 |
| Feb 21, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $200.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $180.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Dec 17, 2024 | Canaccord Genuity | Kyle Mikson | Hold | Initiates | $165.00 |
| Nov 14, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
| Sep 26, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $205.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $180.00 |
| Aug 5, 2024 | Benchmark | Robert Wasserman | Hold | Reiterates | $0.00 |
| Jul 31, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $200.00 |
| Jul 31, 2024 | UBS | Elizabeth Garcia | Buy | Maintains | $185.00 |
| Jul 31, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $190.00 |
| Jul 30, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $170.00 |
| Jun 26, 2024 | Deutsche Bank | Justin Bowers | Buy | Upgrade | $155.00 |
| Jun 18, 2024 | Guggenheim | Subbu Nambi | Neutral | Initiates | $0.00 |
Repligen Corporation (RGEN) Competitors
The following stocks are similar to Repligen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Repligen Corporation (RGEN) Financial Data
Repligen Corporation has a market capitalization of $8.16B with a P/E ratio of 511.1x. The company generates $634.44M in trailing twelve-month revenue with a -4.0% profit margin.
Revenue growth is +0.6% quarter-over-quarter, while maintaining an operating margin of +18.3% and return on equity of -1.3%.
Valuation Metrics
Market Cap
$8.16B
Enterprise Value
$8.06B
P/E Ratio
511.1x
PEG Ratio
81.3x
Price/Sales
12.9x
Growth & Margins
Revenue Growth (YoY)
+0.6%
Gross Margin
+23.2%
Operating Margin
+18.3%
Net Margin
-4.0%
EPS Growth
+7.6%
Financial Health
Cash/Price Ratio
+9.3%
Current Ratio
8.4x
Debt/Equity
34.8x
ROE
-1.3%
ROA
+0.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Repligen Corporation (RGEN) Business Model
About Repligen Corporation
What They Do
Develops bioprocessing technologies for pharmaceuticals.
Business Model
Repligen Corporation operates by developing and supplying essential bioprocessing technologies that enhance the efficiency of biologic drug manufacturing. The company generates revenue through the sale of a diverse range of products, including chromatography resins and filtration technologies, which are critical for the production of biologics such as antibodies and gene therapies.
Additional Information
Headquartered in Waltham, Massachusetts, Repligen has established a strong market presence due to its innovative solutions that meet the increasing demand for biopharmaceuticals. As the biopharmaceutical sector expands, driven by the need for targeted and personalized therapies, Repligen's contributions are becoming increasingly vital to the industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,778
CEO
Mr. Olivier Loeillot
Country
United States
IPO Year
1990
Website
www.repligen.comRepligen Corporation (RGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 23, 2025
By Zacks Equity Research
Tale of the Tape
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 22, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Repligen (RGEN) has a strong history of earnings surprises and is well-positioned for a positive outcome in its upcoming quarterly report.
Why It Matters
Repligen's strong earnings surprise history and favorable indicators suggest potential positive performance in the upcoming report, influencing investor sentiment and stock movement.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Repligen (RGEN) is expected to report earnings that may exceed forecasts, driven by strong key performance indicators. Investors should watch for the upcoming earnings report.
Why It Matters
Repligen's potential earnings beat may indicate strong financial performance, influencing stock price positively and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Genmab A/S (GMAB) and Repligen (RGEN) are notable stocks in the Medical - Biomedical and Genetics sector, appealing to value investors.
Why It Matters
The comparison of Genmab A/S and Repligen highlights potential investment opportunities in biomedical stocks, influencing value-focused investment decisions and portfolio strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Repligen Corporation (NASDAQ:RGEN) appointed Jacob Johnson as Vice President of Investor Relations, overseeing engagement with investors and reporting to CFO Jason K. Garland.
Why It Matters
The appointment of Jacob Johnson enhances Repligen's investor relations, signaling a focus on improved communication and potential strategic insights, which may influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Repligen (RGEN) shares rose on high trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters
Repligen's share price surge on high volume indicates short-term interest, but stagnant earnings estimates may signal potential future weakness, affecting long-term investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Repligen: Ongoing Bioprocessing Market Recovery
1 month ago
Quick Summary
Repligen maintains a 'buy' rating with a $175 price target, fueled by 3% organic revenue growth and a strong bioprocessing market. Recent acquisition boosts its analytics capabilities.
Why It Matters
Repligen's strong revenue growth, high order intakes, and strategic acquisition position it well for future gains, making the 'buy' rating and price target relevant for investment decisions.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About RGEN Stock
What is Repligen Corporation's (RGEN) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Repligen Corporation (RGEN) has a median price target of $190.00. The highest price target is $225.00 and the lowest is $140.00.
Is RGEN stock a good investment in 2025?
According to current analyst ratings, RGEN has 13 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $144.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGEN stock?
Wall Street analysts predict RGEN stock could reach $190.00 in the next 12 months. This represents a 31.3% increase from the current price of $144.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repligen Corporation's business model?
Repligen Corporation operates by developing and supplying essential bioprocessing technologies that enhance the efficiency of biologic drug manufacturing. The company generates revenue through the sale of a diverse range of products, including chromatography resins and filtration technologies, which are critical for the production of biologics such as antibodies and gene therapies.
What is the highest forecasted price for RGEN Repligen Corporation?
The highest price target for RGEN is $225.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 55.4% increase from the current price of $144.75.
What is the lowest forecasted price for RGEN Repligen Corporation?
The lowest price target for RGEN is $140.00 from at , which represents a -3.3% decrease from the current price of $144.75.
What is the overall RGEN consensus from analysts for Repligen Corporation?
The overall analyst consensus for RGEN is bullish. Out of 19 Wall Street analysts, 13 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $190.00.
How accurate are RGEN stock price projections?
Stock price projections, including those for Repligen Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 8:10 PM UTC